Comorbidity and prognosis in head and neck cancers: Differences by subsite, stage, and human papillomavirus status

Head & Neck ◽  
2013 ◽  
Vol 36 (6) ◽  
pp. 802-810 ◽  
Author(s):  
Steven Habbous ◽  
Luke T. G. Harland ◽  
Anthony La Delfa ◽  
Ehab Fadhel ◽  
Wei Xu ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Head And Neck Cancers

Psychosocial outcomes of human papillomavirus (HPV)‐ and non‐HPV‐related head and neck cancers: A longitudinal study

2021 ◽  
Author(s):  
Melissa Henry ◽  
Emily Arnovitz ◽  
Saul Frenkiel ◽  
Michael Hier ◽  
Anthony Zeitouni ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Longitudinal Study ◽  
Head And Neck ◽  
Psychosocial Outcomes ◽  
Head And Neck Cancers

scholarly journals Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates

2018 ◽  
Vol 95 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Koh Jun Ong ◽  
Marta Checchi ◽  
Lorna Burns ◽  
Charlotte Pavitt ◽  
Maarten J Postma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Human Papillomavirus ◽  
Head And Neck ◽  
Anal Cancer ◽  
Penile Cancer ◽  
Vulvar Cancer ◽  
Head And Neck Cancers ◽  
Economic Evaluations ◽  
Anogenital Warts ◽  
Utility Elicitation

BackgroundMany economic evaluations of human papillomavirus vaccination should ideally consider multiple disease outcomes, including anogenital warts, respiratory papillomatosis and non-cervical cancers (eg, anal, oropharyngeal, penile, vulvar and vaginal cancers). However, published economic evaluations largely relied on estimates from single studies or informal rapid literature reviews.MethodsWe conducted a systematic review of articles up to June 2016 to identify costs and utility estimates admissible for an economic evaluation from a single-payer healthcare provider’s perspective. Meta-analyses were performed for studies that used same utility elicitation tools for similar diseases. Costs were adjusted to 2016/2017 US$.ResultsSixty-one papers (35 costs; 24 utilities; 2 costs and utilities) were selected from 10 742 initial records. Cost per case ranges were US$124–US$883 (anogenital warts), US$6912–US$52 579 (head and neck cancers), US$12 936–US$51 571 (anal cancer), US$17 524–34 258 (vaginal cancer), US$14 686–US$28 502 (vulvar cancer) and US$9975–US$27 629 (penile cancer). The total cost for 14 adult patients with recurrent respiratory papillomatosis was US$137 601 (one paper).Utility per warts episode ranged from 0.651 to 1 (12 papers, various utility elicitation methods), with pooled mean EQ-5D and EQ-VAS of 0.86 (95% CI 0.85 to 0.87) and 0.74 (95% CI 0.74 to 0.75), respectively. Fifteen papers reported utilities in head and neck cancers with range 0.29 (95% CI 0.0 to 0.76) to 0.94 (95% CI 0.3 to 1.0). Mean utility reported ranged from 0.5 (95% CI 0.4 to 0.61) to 0.65 (95% CI 0.45 to 0.75) (anal cancer), 0.59 (95% CI 0.54 to 0.64) (vaginal cancer), 0.65 (95% CI 0.60 to 0.70) (vulvar cancer) and 0.79 (95% CI 0.74 to 0.84) (penile cancer).ConclusionsDifferences in values reported from each paper reflect variations in cancer site, disease stages, study population, treatment modality/setting and utility elicitation methods used. As patient management changes over time, corresponding effects on both costs and utility need to be considered to ensure health economic assumptions are up-to-date and closely reflect the case mix of patients.

Human papillomavirus: a cause of some head and neck cancers?

2004 ◽  
Vol 181 (8) ◽  
pp. 415-416 ◽  
Author(s):  
Barbara R Rose ◽  
Christopher J O'Brien ◽  
Wei Li
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Head And Neck Cancers

scholarly journals Human papillomavirus and head and neck cancers: emerging trends and improving survival

2012 ◽  
Vol 36 (2) ◽  
pp. 195-196 ◽  
Author(s):  
Julia M.L. Brotherton ◽  
Alicia N. Stein ◽  
E. Lynne Conway ◽  
David G. Regan ◽  
Andrew Grulich ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Emerging Trends

scholarly journals Human papillomavirus as a driver of head and neck cancers

2019 ◽  
Vol 122 (3) ◽  
pp. 306-314 ◽  
Author(s):  
Maria Elisa Sabatini ◽  
Susanna Chiocca
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Hpv Infection ◽  
Head And Neck Cancers ◽  
Molecular Characteristics ◽  
Pathogenic Role ◽  
Diagnostic Biomarkers ◽  
Different Types ◽  
High Risk Hpv ◽  
Racial Ethnic

Abstract The human papillomavirus (HPV) family includes more than 170 different types of virus that infect stratified epithelium. High-risk HPV is well established as the primary cause of cervical cancer, but in recent years, a clear role for this virus in other malignancies is also emerging. Indeed, HPV plays a pathogenic role in a subset of head and neck cancers—mostly cancers of the oropharynx—with distinct epidemiological, clinical and molecular characteristics compared with head and neck cancers not caused by HPV. This review summarises our current understanding of HPV in these cancers, specifically detailing HPV infection in head and neck cancers within different racial/ethnic subpopulations, and the differences in various aspects of these diseases between women and men. Finally, we provide an outlook for this disease, in terms of clinical management, and consider the issues of ‘diagnostic biomarkers’ and targeted therapies.

scholarly journals Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers

Cancers ◽  
2020 ◽  
Vol 12 (1) ◽  
pp. 253 ◽  
Author(s):  
Martin A. Prusinkiewicz ◽  
Steven F. Gameiro ◽  
Farhad Ghasemi ◽  
Mackenzie J. Dodge ◽  
Peter Y. F. Zeng ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Patient Survival ◽  
Tricarboxylic Acid Cycle ◽  
Predictive Biomarkers ◽  
Head And Neck Cancers ◽  
The Cancer Genome Atlas ◽  
Metabolic Genes ◽  
Hpv Status ◽  
The Impact

Human papillomavirus (HPV) causes an increasing number of head and neck squamous cell carcinomas (HNSCCs). Altered metabolism contributes to patient prognosis, but the impact of HPV status on HNSCC metabolism remains relatively uncharacterized. We hypothesize that metabolism-related gene expression differences unique to HPV-positive HNSCC influences patient survival. The Cancer Genome Atlas RNA-seq data from primary HNSCC patient samples were categorized as 73 HPV-positive, 442 HPV-negative, and 43 normal-adjacent control tissues. We analyzed 229 metabolic genes and identified numerous differentially expressed genes between HPV-positive and negative HNSCC patients. HPV-positive carcinomas exhibited lower expression levels of genes involved in glycolysis and higher levels of genes involved in the tricarboxylic acid cycle, oxidative phosphorylation, and β-oxidation than the HPV-negative carcinomas. Importantly, reduced expression of the metabolism-related genes SDHC, COX7A1, COX16, COX17, ELOVL6, GOT2, and SLC16A2 were correlated with improved patient survival only in the HPV-positive group. This work suggests that specific transcriptional alterations in metabolic genes may serve as predictive biomarkers of patient outcome and identifies potential targets for novel therapeutic intervention in HPV-positive head and neck cancers.

scholarly journals Salivary High-Risk Human Papillomavirus DNA as a Biomarker for Human Papillomavirus–Driven Head and Neck Cancers

2021 ◽  
Author(s):  
Chameera Ekanayake Weeramange ◽  
Zhen Liu ◽  
Gunter Hartel ◽  
Yinan Li ◽  
Sarju Vasani ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
High Risk ◽  
Head And Neck ◽  
Head And Neck Cancers ◽  
Papillomavirus Dna
Sign in / Sign up

Export Citation Format

Share Document